Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims are not supported by the provided prescribing information excerpts, particularly regarding generic substitution/therapeutic equivalence, dispensing practices, cost, and patient switching guidance. The response also introduces several safety/clinical-use assertions not substantiated in the supplied label text (e.g., specific GI side effects framing and weight-appetite linkage), while only a subset of label-backed facts (dosing, titration existence, weight decrease monitoring, psychiatric risk in depression history, and not a bronchodilator) aligns with the excerpts.
Category Scores
Accurate Statements
Roflumilast/ DALIRESP is not a bronchodilator and should not be used for immediate relief of acute bronchospasm (rescue medication).
Sections 5.1 and 14.1: “DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm.”
Weight loss was reported as a common adverse reaction and patients should have weight monitored regularly; evaluate unexplained clinically significant weight loss and consider discontinuation.
Section 5.3: “Weight loss was a common adverse reaction… Patients treated with DALIRESP should have their weight monitored regularly… If unexplained or clinically significant weight loss occurs… discontinuation… should be considered.”
Psychiatric events including suicidality are associated with DALIRESP, and prescribers should weigh risks/benefits before use in patients with a history of depression and/or suicidal thoughts or behavior.
Section 5.2: “Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions… instances of suicidal… observed…” and “Before using DALIRESP in patients with a history of depression and/or suicidal thoughts… prescribers should carefully weigh the risks and benefits…”
DALIRESP has tablet strengths of 250 mcg and 500 mcg and a starting titration of 250 mcg once daily for 4 weeks then increase to 500 mcg once daily thereafter.
Section 2: maintenance dose “one 500 micrograms (mcg) tablet per day” and starting “250 mcg once daily for 4 weeks… increasing to 500 mcg once daily thereafter.”
Unsupported Statements
Daliresp is brand-name roflumilast.
The provided excerpts state “DALIRESP® (roflumilast)” but do not explicitly assert that Daliresp is the brand name of roflumilast (it is implied by labeling name formatting, but not directly supported as a standalone claim).
Generic roflumilast is available in many markets as the same active ingredient.
No information about generic availability by market is present in the provided label excerpts.
Generics use the same drug substance as Daliresp.
No generic substitution/manufacturing equivalence statements exist in the provided label excerpts.
Generic roflumilast is intended to provide the same effect as Daliresp when taken at the prescribed dose.
No therapeutic equivalence guidance for generics is present in the provided label excerpts.
Switching from Daliresp to generic roflumilast is usually based on the same active ingredient with a different brand.
No statement about switching generics/brands is present in the provided label excerpts.
Daliresp is commonly dispensed as roflumilast 250 mcg tablets.
The label excerpt does not discuss common dispensing practices.
Daliresp is commonly dispensed as roflumilast 500 mcg tablets.
The label excerpt does not discuss common dispensing practices.
When switching, patients should use the same dosing schedule prescribed by the clinician.
No patient switching instruction is provided in the excerpts.
Inactive ingredients can differ between products even when the active ingredient is the same.
No excipient-related statements are present in the provided excerpts.
After switching, some patients may notice a change in side effects.
No generic switching/cause-effect statement about side effects after switching is present in the provided excerpts.
Generic roflumilast is approved to be therapeutically equivalent to the branded product.
No regulatory equivalence (e.g., “therapeutically equivalent”) statement for generics is present in the provided label excerpts.
Generic roflumilast should work the same way as Daliresp for the same indications when dosed appropriately.
No statement about generic substitution equivalence is present in the provided label excerpts.
If a patient is stable on Daliresp, staying on the same roflumilast strength and schedule is typically the most important step.
No such clinical switching/stability guidance is present in the excerpts.
Roflumilast commonly has gastrointestinal system side effects.
While diarrhea and nausea appear in the adverse reaction section excerpt, the response broadens this to “commonly has gastrointestinal system side effects” as a general category; the excerpt provides specific events but does not label them as a GI “system” category.
Roflumilast commonly affects appetite.
Appetite is not mentioned in the provided label excerpts.
Some patients report weight loss with roflumilast.
Weight loss is described as common; however this generic phrasing is not necessary and is not tied to specific label language beyond “Weight loss was a common adverse reaction.” The statement is not directly supported as written (it is at least conceptually aligned, but the excerpt specifically says weight loss was common; still, no “some patients report” phrasing support).
Patients with a history of low body weight should especially talk with their prescriber before changing products or continuing therapy.
The excerpt does not mention “low body weight” history or any switching/“before changing products” instruction.
Patients with a history of unintentional weight loss should especially talk with their prescriber before changing products or continuing therapy.
The excerpt discusses monitoring and evaluating unexplained clinically significant weight loss and considering discontinuation, but does not provide “history of unintentional weight loss” counseling language nor “before changing products.”
Patients with bothersome nausea/diarrhea should especially talk with their prescriber before changing products or continuing therapy.
The excerpt lists nausea/diarrhea and weight loss but does not provide counseling instructions framed as “especially talk… before changing products.”
In many cases, generic roflumilast costs less than brand Daliresp.
Cost is not addressed in the provided label excerpts.
Patients should compare cash price (or copay) at their local pharmacy for roflumilast at the same dose for the most accurate cost comparison.
Pharmacy cost comparison advice is not present in the provided label excerpts.
Patients generally should not "mix and match" roflumilast strengths.
No instruction about mixing/matching strengths is present in the excerpts.
Patients should confirm the exact dose on the prescription (e.g., 250 mcg vs 500 mcg).
The label provides dosing regimen details but does not provide patient instructions about confirming the exact dose.
Roflumilast regimens may include starter titration and a maintenance dose.
Titration and maintenance are described, but the phrase “may include” and framing as a regimen component is not explicitly stated as such; while consistent with label, it is still more interpretive than directly quoted.
Patients should confirm whether they are using starter titration or a maintenance dose if their regimen includes it.
No patient instruction is present in the excerpts.
Upon picking up a prescription, confirming that it is generic roflumilast and what strength it is helps match the Daliresp dose and avoids accidental under- or over-dosing.
Generic substitution guidance and “avoids accidental under- or over-dosing” rationale are not present in the provided excerpts.
Contradictions
Low
AI Statement
None of the provided claims directly contradict the supplied label excerpts.
Label Reference
N/A
Important Omissions
Missing boxed warning status: The provided excerpts do not include any boxed warning text; however the response does not mention key label warnings about contraindication in moderate/severe liver impairment (Child-Pugh B/C).
Importance:
Moderate
Drug interaction warning: The label excerpt specifically advises against strong CYP enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) and notes increased exposure with CYP3A4 inhibitors/dual inhibitors. The response does not mention these interaction precautions.
Importance:
High
Acute bronchospasm/rescue limitation is not stated in the response list as a claim; it is included in the label but the user claims list does not include it.
Importance:
Moderate
Not recommended during labor and delivery; pediatric and geriatric/renal/liver-specific considerations (especially hepatic impairment contraindication/not recommended) are not addressed in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Key label elements relevant to safe use—strong CYP inducer avoidance and hepatic impairment restrictions—are not addressed, and multiple statements about switching/generic equivalence are unsupported by the provided label excerpts, which could lead to inappropriate reliance on unlabelled guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims about generic substitution/therapeutic equivalence, patient switching/counseling, cost, and safety concerns are not supported by the supplied prescribing information excerpts; important label precautions (CYP inducers and hepatic impairment) are omitted.
Suggested Improvement
Restrict statements to label-supported facts from the provided excerpts: COPD exacerbation indication; dosing (250 mcg x 4 weeks then 500 mcg maintenance); contraindication/not recommended for Child-Pugh B/C hepatic impairment; not a bronchodilator/rescue; psychiatric warning and weight monitoring; and drug interaction precautions (avoid strong CYP inducers; note increased exposure with CYP inhibitors). Remove or qualify generics/switching/cost statements unless supported by label text.